Keuangan Moderna, Inc. (MRNA)
NASDAQ · Healthcare · Biotechnology · Karyawan: 4.700 · CEO: Stéphane Bancel
- Harga
- $221,72 -0,47%
- Kapitalisasi pasar
- $88,5 M
- Nilai perusahaan
- $88,1 M
- Laporan terakhir
- Q2 '26 diajukan 2026-07-31
- Laporan berikutnya
- 2026-11-06
Valuasi & angka utama
- Kapitalisasi pasar
- $88,5 M EV $88,1 M
- Pendapatan
- $2,23 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +8% Konsensus FY2026
- Margin laba
- -141,4% Laba bersih / pendapatan, TTM
- P/E
- -27,8× Forward -26,3× (FY2026)
- P/S
- 39,7× Harga / penjualan, TTM
- EV / EBITDA
- -31,1× TTM
- Arus kas bebas
- -$1,22 M 12 bulan terakhir
- Laba bersih
- -$3,15 M 12 bulan terakhir
- Estimasi pendapatan
- $2,1 M Konsensus FY2026
- Laba
- 2026-11-06
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-07-31): pendapatan melampaui 40,9%, EPS melampaui 3,0%Pendapatan $145 jt vs $103 jt yang diharapkan (+40,9%); EPS -$1,97 vs -$2,03 (+3,0%).
- Pertumbuhan pendapatan melambat: 2,1% yoyPendapatan Q2 '26: $145 jt, rata-rata empat kuartal sebelumnya: 38,4%.
- Margin operasional -149,0% (TTM), dibanding tahun lalu: -42,1 poinLaba operasional tumbuh -1,4%, pendapatan tumbuh -27,2%.
- Capex: 7,7% dari pendapatan (tahun lalu 26,2%)$171 jt diinvestasikan dalam 4 kuartal terakhir (-78,7% dibanding tahun sebelumnya). Arus kas bebas: -$1,22 M.
- Jumlah saham dilusian naik dalam setahun: 2,1%Saham dilusian pada Q2 '26: 396 jt, setahun sebelumnya: 388 jt.
- Kas neto: $3,85 MKas + investasi jangka pendek: $5,14 M, utang termasuk sewa: $1,29 M; tahun lalu kas neto: $4,39 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $145 jt | $142 jt | +2,1% |
| Margin kotor | 35,9% | 16,2% | +19,7 poin |
| Laba operasional | -$815 jt | -$907 jt | +10,1% |
| Margin operasional | -562,1% | -638,7% | +76,7 poin |
| Laba bersih | -$782 jt | -$825 jt | +5,2% |
| EPS dilusian | -$1,96 | -$2,13 | +8,0% |
| Arus kas operasional | -$526 jt | -$919 jt | +42,8% |
| Capex | $37 jt | $3 jt | +1.133,3% |
| Arus kas bebas | -$563 jt | -$922 jt | +38,9% |
| R&D | $651 jt | $700 jt | -7,0% |
| Kompensasi berbasis saham | $120 jt | $130 jt | -7,7% |
Dilaporkan vs konsensus
2026-07-31| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $145 jt | $103 jt | +40,9% |
| EPS (basis konsensus) | -$1,97 | -$2,03 | +3,0% |
Dari laporan 2026-07-31 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Product Sales | $171 jt | -2,8% | 100,0% | $3,55 M | -2,3% |
Pendapatan per wilayah
porsi dari total| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Rest Of The World | $8 jt | -69,2% | 8,5% | $570 jt | -28,9% | |
| United States | $70 jt | -20,5% | 74,5% | $1,22 M | -25,5% | |
| Europe | $16 jt | – | 17,0% | $308 jt | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$1,05 M
- Capex
- -$171 jt
- Buyback
- -$2 jt
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- $542 jt
- Kompensasi berbasis saham
- $349 jt
- Arus kas bebas
- -$1,22 M
- Dikembalikan ke pemegang saham / FCF
- -0,2%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -27,8× | 8,4× 2 dari 5 tahun | 8,4× – 8,4× |
| EV / EBITDA | -31,1× | 7,0× 2 dari 5 tahun | 6,9× – 7,1× |
| EV / Penjualan | 39,5× | 4,9× | 3,6× – 5,6× |
| Harga / FCF | -72,4× | 11,6× 2 dari 5 tahun | 7,7× – 15,4× |
| Harga / Nilai buku | 13,0× | 3,3× | 1,3× – 7,2× |
| Imbal hasil FCF | -1,4% | -6,8% | -25,4% – 13,0% |
| Imbal hasil modal yang diinvestasikan | -39,2% | 5,4% | -32,5% – 77,5% |
| Imbal hasil ekuitas | -39,2% | 6,1% | -34,0% – 86,3% |
Analis
Target konsensus $132,70 (-40,1%)
rentang $25,00 – $245,00 · peringkat Hold
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $2,1 M | +8,1% | -$8,42 | -16,0% | -26,3× | 17 |
| FY2027 | $2,43 M | +15,9% | -$4,76 | +43,5% | -46,6× | 16 |
| FY2028 | $3,38 M | +38,8% | -$2,85 | +40,1% | -77,8× | 15 |
| FY2029 | $5,56 M | +64,5% | $0,36 | +112,5% | 623,6× | 9 |
| FY2030 | $7,58 M | +36,4% | $3,52 | +890,4% | 63,0× | 6 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 286 angka yang ditandai Moderna, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $167 jt | $175 jt | -4,6% | $317 jt | $405 jt | -21,7% |
| Accounts Receivable, after Allowance for Credit Loss | $17 jt | $36 jt | -52,8% | $184 jt | $358 jt | -48,6% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $17 jt | $36 jt | -52,8% | $184 jt | $358 jt | -48,6% |
| Accounts Receivable, Allowance for Credit Loss | $6 jt | $12 jt | -50,0% | $3 jt | $0 | – |
| Accounts Receivable, Allowance for Credit Loss, Current | $02025-12-31 | $0 | – | $0 | $0 | – |
| Accounts Receivable, before Allowance for Credit Loss | $120 jt | $260 jt | -53,8% | $368 jt | $698 jt | -47,3% |
| Accounts Receivable, Credit Loss Expense (Reversal) | – | – | – | $0 | $0 | – |
| Accrued Liabilities, Current | $1,91 M | $987 jt | +93,4% | $1,39 M | $1,43 M | -2,9% |
| Accrued Royalties, Current | $954 jt | $6 jt | +15.800,0% | $31 jt | $46 jt | -32,6% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $19 jt | $23 jt | -17,4% | $45 jt | -$10 jt | +550,0% |
| Additional Paid in Capital | $1,64 M | $1,13 M | +45,9% | $1,38 M | $866 jt | +59,6% |
| Advertising Expense | – | – | – | $133 jt | $146 jt | -8,9% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 42 jt | 46 jt | -8,7% | 38 jt | 34 jt | +11,8% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $120 jt | $130 jt | -7,7% | $483 jt | $429 jt | +12,6% |
| Asset Impairment Charges | – | – | – | $0 | $0 | – |
| Assets | $11 M | $12 M | -8,7% | $12,3 M | $14,1 M | -12,8% |
| Assets, Current | $5,82 M | $6,17 M | -5,8% | $6,54 M | $8,1 M | -19,2% |
| Capital Expenditures Incurred but Not yet Paid | $1 jt | -$3 jt | +133,3% | $83 jt | $97 jt | -14,4% |
| Cash and Cash Equivalents, at Carrying Value | $1,72 M | $1,28 M | +34,7% | $2,6 M | $1,93 M | +34,7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1,72 M | $1,28 M | +34,6% | $2,6 M | $1,93 M | +34,6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$185 jt | -$345 jt | +46,4% | $668 jt | -$999 jt | +166,9% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 1,6 M | 1,6 M | 0,0% | 1,6 M | 1,6 M | 0,0% |
| Common Stock, Shares, Issued | 399 jt | 389 jt | +2,6% | 394 jt | 386 jt | +2,1% |
| Common Stock, Shares, Outstanding | 399 jt | 389 jt | +2,6% | 394 jt | 386 jt | +2,1% |
| Common Stock, Value, Issued | $0 | $0 | – | $0 | $0 | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$788 jt | -$812 jt | +3,0% | -$2,77 M | -$3,45 M | +19,8% |
| Contract with Customer, Liability | $442 jt | $283 jt | +56,2% | $252 jt | $211 jt | +19,4% |
| Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress | $235 jt | $134 jt | +75,4% | $320 jt | $264 jt | +21,2% |
| Contract with Customer, Liability, Current | $295 jt | $218 jt | +35,3% | $99 jt | $153 jt | -35,3% |
| Contract with Customer, Liability, Noncurrent | $147 jt | $65 jt | +126,2% | $153 jt | $58 jt | +163,8% |
| Contract with Customer, Refund Liability | $421 jt | $308 jt | +36,7% | $509 jt | $370 jt | +37,6% |
| Cost of Goods and Services Sold | $93 jt | $119 jt | -21,8% | $868 jt | $1,46 M | -40,7% |
| Costs and Expenses | $960 jt | $1,05 M | -8,5% | $5,02 M | $7,18 M | -30,1% |
| Current Federal Tax Expense (Benefit) | – | – | – | $11 jt | -$57 jt | +119,3% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $29 jt | $13 jt | +123,1% |
| Current Income Tax Expense (Benefit) | – | – | – | $44 jt | -$45 jt | +197,8% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $4 jt | -$1 jt | +500,0% |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $5,2 M | $6,23 M | -16,5% | $5,53 M | $7,61 M | -27,3% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $1,78 M | $2,38 M | -25,0% | $2,33 M | $2,51 M | -6,9% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $3,42 M | $3,85 M | -11,2% | $3,2 M | $5,11 M | -37,3% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $3 jt | $7 jt | -57,1% | $3 jt | $22 jt | -86,4% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | $264 jt | $567 jt | -53,4% | $283 jt | $2,64 M | -89,3% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $13 jt | $2 jt | +550,0% | $1 jt | $6 jt | -83,3% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | $3,75 M | $2 M | +88,0% | $931 jt | $1,67 M | -44,4% |
| Debt Securities, Available-for-sale, Current | $3,42 M | $3,85 M | -11,3% | $3,2 M | $5,1 M | -37,2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $1,77 M | $2,37 M | -25,4% | $2,34 M | $2,49 M | -6,3% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $3,42 M | $3,85 M | -11,3% | $3,2 M | $5,1 M | -37,2% |
| Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value | $5,19 M | $6,23 M | -16,7% | $5,54 M | $7,59 M | -27,0% |
| Debt Securities, Available-for-sale, Noncurrent | $1,77 M | $2,37 M | -25,4% | $2,34 M | $2,49 M | -6,3% |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $16 jt | $9 jt | +77,8% | $4 jt | $28 jt | -85,7% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $4,02 M | $2,56 M | +56,7% | $1,21 M | $4,32 M | -71,9% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | 283 security | 140 security | +102,1% | 108 security | 252 security | -57,1% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $10 jt | -$1 jt | +1.100,0% |
| Deferred Income Tax Assets, Net | $82 jt | $81 jt | +1,2% | $81 jt | $81 jt | 0,0% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $10 jt | -$1 jt | +1.100,0% |
| Deferred Income Tax Liabilities, Net | $255 jt | $237 jt | +7,6% | $249 jt | $231 jt | +7,8% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01